Literature DB >> 11936466

Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.

M Gasperi1, E Martino, L Manetti, M Arosio, S Porretti, G Faglia, S Mariotti, A M Colao, G Lombardi, R Baldelli, F Camanni, A Liuzzi.   

Abstract

Acromegaly is frequently associated with the presence of thyroid disorders, however the exact prevalence is still controversial. An Italian multicenter study was performed on 258 patients with active acromegaly (high levels of IGF-I and lack of suppression of serum GH levels below 2 microg/l after an OGTT). The control group was represented by 150 patients affected by non-functioning and PRL-secreting pituitary adenomas. Two hundred and two out of 258 acromegalic patients (78%) were affected by thyroid disorders with a significantly higher prevalence with respect to the control group (27%, p<0.0001). One hundred and three patients presented (39.9%) non-toxic nodular goiter, 46 (17.8%) non-toxic diffuse goiter, 37 (14.3%) toxic nodular goiter, 1 toxic diffuse goiter (0.4%), 12 (4.6%) Hashimoto's thyroiditis, 3 (1.2%) thyroid cancer. Two patients presented a co-secreting TSH pituitary adenoma. Thirty-six patients had been previously treated for various thyroid abnormalities. Among the 222 acromegalic patients never treated for thyroid disorders thyroid ultrasonography was performed on 194 subjects. Thyroid volume in patients with thyroid abnormalities was 28+/-17.5 ml (median 23) while it was 10.8+/-3.6 ml (median 10) in patients without thyroid disorders (p<0.0001). Thyroid volume was correlated with the estimated duration of acromegaly (r=0.7, p<000.1), but not with age or with serum GH, IGF-I and TSH concentrations. Thyroid volume was higher in acromegalic patients than in the above control population (23.5+/-16.9 ml vs 13.9+/-12.8 ml, p<0.0001). In 62 acromegalic patients 101 fine-needle biopsies of thyroid nodules were performed; 7 nodules were suspicious and the patients were submitted to thyroid surgery: papillary thyroid carcinoma was found in 3 patients. In conclusion, in a large series of acromegalic patients an increased prevalence of thyroid disorders (78%), particularly non-toxic nodular goiter, has been observed. Thyroid volume, evaluated by ultrasonography, was correlated to the estimated duration of acromegaly. Finally, the prevalence of thyroid carcinoma was slightly increased than in the general population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936466     DOI: 10.1007/BF03343997

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

Review 1.  Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?

Authors:  S Ezzat; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958

2.  Thyroid volume and function in patients with acromegaly living in iodine deficient areas.

Authors:  R Junik; J Sawicka; W Kozak; M Gembicki
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

3.  Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

Authors:  A Colao; P Marzullo; D Ferone; V Marinò; R Pivonello; C Di Somma; A Di Sarno; A Giaccio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

4.  Increased incidence of neoplasia in females with acromegaly.

Authors:  N W Cheung; S C Boyages
Journal:  Clin Endocrinol (Oxf)       Date:  1997-09       Impact factor: 3.478

5.  Benign and malignant tumors in patients with acromegaly.

Authors:  J Barzilay; G J Heatley; G W Cushing
Journal:  Arch Intern Med       Date:  1991-08

6.  Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland.

Authors:  K Kasagi; A Shimatsu; S Miyamoto; T Misaki; H Sakahara; J Konishi
Journal:  Thyroid       Date:  1999-08       Impact factor: 6.568

7.  The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey.

Authors:  F Aghini-Lombardi; L Antonangeli; E Martino; P Vitti; D Maccherini; F Leoli; T Rago; L Grasso; R Valeriano; A Balestrieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

8.  An association between acromegaly and thyroid carcinoma.

Authors:  C Balkany; G W Cushing
Journal:  Thyroid       Date:  1995-02       Impact factor: 6.568

9.  Endemic goiter and thyroid function in central-southern Sardinia. Report on an extensive epidemiological survey.

Authors:  E Martino; A Loviselli; F Velluzzi; M L Murtas; M Carta; M Lampis; R Murru; A Mastinu; M L Arba; V Sica
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

10.  Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine.

Authors:  L C Hofbauer; M Rafferzeder; O E Janssen; R Gärtner
Journal:  Eur J Endocrinol       Date:  1995-05       Impact factor: 6.664

View more
  33 in total

1.  Acromegaly and thyroid.

Authors:  Klaus von Werder
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 2.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 3.  Complications of acromegaly: thyroid and colon.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Thyroid cancer is the most common cancer associated with acromegaly.

Authors:  Bennur Esen Gullu; Ozlem Celik; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

5.  Increased thyroid cancer risk in acromegaly.

Authors:  Selcuk Dagdelen; Nese Cinar; Tomris Erbas
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

6.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064

Review 7.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

8.  A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.

Authors:  C Urbani; D Russo; F Raggi; M Lombardi; C Sardella; I Scattina; I Lupi; L Manetti; L Tomisti; C Marcocci; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2014-07-05       Impact factor: 4.256

9.  Adrenal morpho-functional alterations in patients with acromegaly.

Authors:  C Scaroni; R Selice; S Benedini; E De Menis; M Arosio; C Ronchi; M Gasperi; L Manetti; G Arnaldi; B Polenta; M Boscaro; N Albiger; E Martino; F Mantero
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

10.  Expression and significance of IGF-1 and IGF-1R in thyroid nodules.

Authors:  Ying-Jian Liu; Wei Qiang; Jing Shi; Si-Qing Lv; Mei-Ju Ji; Bing-Yin Shi
Journal:  Endocrine       Date:  2013-01-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.